Videos de Experimentos Relacionados

Alta dosis de melfalan para el mieloma múltiple.

M Cavo, M Baccarani, M Gobbi

Lancet (London, England)

|November 19, 1983

Resumen

No abstract available in PubMed .

Videos de Conceptos Relacionados

También podría leer

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

European journal of haematology·2026

Same author

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

Clinical and experimental medicine·2025

Same author

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Journal of cancer research and clinical oncology·2025

Same author

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

Journal of bone oncology·2025

Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Same author

Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.

Cancer medicine·2024

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

Ver todos los artículos relacionados

Videos de Experimentos Relacionados

Alta dosis de melfalan para el mieloma múltiple.

Videos de Conceptos Relacionados

Artículos Relacionados

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Videos de Experimentos Relacionados

Alta dosis de melfalan para el mieloma múltiple.

Videos de Conceptos Relacionados

Artículos Relacionados

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.